As a molecular marker of progenitor cells, CD34 often expresses in low-grade or developmental brain tumors, which are usually accompanied by chronic epilepsy, such as the so-called “low-grade epilepsy-associated neuroepithelial tumors (LEAT),” but none of normal adult or developing human brain and tumors without epilepsy are CD34 positive (Blümcke et al., 1999; Deb et al., 2006; Chappé et al., 2013; Sidney et al., 2014; Giulioni et al., 2019). Here, CD34 is linked to epilepsy.